Topline outcome and trial specifics
Pharvaris NV saw its stock climb after releasing topline data from CHAPTER-3, a global, double-blind, placebo-controlled pivotal Phase 3 study assessing deucrictibant XR as a preventative treatment for hereditary angioedema attacks. The study enrolled 85 adolescents and adults across 21 countries. According to the company, the trial met its primary endpoint, with deucrictibant XR reducing mean monthly HAE attack rates by 83% compared with placebo and producing a p-value below 0.0001.
Pharvaris also reported that all secondary efficacy endpoints were achieved with statistical significance. The company described the treatment as having a well-tolerated safety profile in the study population.
Subgroup and regulatory implications
CHAPTER-3 is notable, the company said, because it is the first and only prophylaxis Phase 3 trial to include patients from all three types of hereditary angioedema. For those with HAE Type 1 or Type 2, the effect was larger, with an 87% reduction in attack rates versus placebo. Pharvaris confirmed it plans to base regulatory submissions on these results, naming a U.S. New Drug Application targeted for the first half of 2027.
Analyst view and prior expectations
Analyst coverage of Pharvaris prior to the readout already skewed positive, with Overweight ratings from Morgan Stanley and Wells Fargo and Buy ratings from Guggenheim, RBC Capital and Oppenheimer. The company said the strength of the CHAPTER-3 data validated the bullish consensus reflected in that coverage.
Market reaction and stock action
The equity response was pronounced and specific to the company. In morning trading the shares rose 12.4%. The S&P 500 and the Nasdaq were both down 0.4% on the same day, indicating the move was driven by the company announcement rather than a broader market uplift. Pharvaris touched a session high of $43.25, which the company identified as a new 52-week high, before settling back to trade around $39.61.
Investors have re-priced the shares strongly following the readout; the company noted that the stock has more than doubled off its 52-week low of $20.65 on a cumulative basis, illustrating the market impact a successful late-stage result can produce for a clinical-stage biopharmaceutical firm.
Takeaway
Taken together, Pharvaris presented a clean primary endpoint, statistically significant secondary outcomes across HAE subtypes, and a regulatory timeline that gives a clear near-term pathway to submission. Those elements underpinned investor confidence and drove the sharp intraday re-rating of the stock.
Summary of key facts
- CHAPTER-3 enrolled 85 adolescents and adults in 21 countries.
- Primary endpoint: mean monthly HAE attack rates reduced 83% versus placebo; p-value < 0.0001.
- HAE Type 1 and Type 2 subgroup: 87% reduction versus placebo.
- Company plans to use these data for regulatory filings, including a U.S. NDA targeted for the first half of 2027.